JPCRPHA@EC2611A

Huaxin Pharmaceutical Subsidiaries Obtain Clinical Trial Approval and Market Approval for New Drugs

Huahuaipuoyi Commerce Completes RMB 3 Billion Medium-Term Note Issuance

Huahuaikang Medicine's Two Drugs Included in National Health Insurance Directory

Huahuaipharma Subsidiary's Pioglitazone Hydrochloride Dispersible Tablets Pass Consistency Evaluation

China Resources Medicine Co., Ltd. Established with a Registered Capital of 30 Million RMB

Shuren Sanjiu Secures Exclusive Rights to Helkos in China

CR Medicine's Five Products Preselected for the 11th National Pharmaceutical Concentrated Procurement

Huamao Pharmaceutical Announces Huansaijiu's Q1-Q3 2025 Performance

China Resources Pharma's ESG rating upgraded to AA

Huaren Medicine's subsidiary obtains certificate for Certrofiban Hydrochloride Sodium Injection

Huaron Medicine Subsidiary Obtains Drug Supplement Approval

Huahuaipu Medicine Subsidiaries Obtain Drug Registration Certificates to Boost Market Competitiveness

BOA Securities Cuts Interim Earnings Forecast and Target Price for China Resources Medicine

CHINARES PHARMA released FY2025 Q1 earnings on August 26, 2025 (BJT) with actual revenue of HKD 70.61 B and EPS of HKD 0.1767

China Resources Medicine Reports Mid-Year Revenue Growth and Profit Decline

CHINARES PHARMA released FY2025 Q2 earnings on August 26 Pre-Market (BJT), actual revenue HKD 72.17 B, actual EPS HKD 0.1806

CHINARES PHARMA released FY2025 Semi-Annual Earnings on August 26 Pre-Market BJT, actual revenue HKD 142.78 B (forecast HKD 146.93 B), actual EPS HKD 0.3573 (forecast HKD 0.448)

Huaren Pharmaceutical's Innovative Antibody Drug Development Project Recognized by State-owned Assets Supervision and Administration Commission

CHINARES PHARMA to release FY2025 Semi-Annual earnings on August 26, 2025 (BJT), forecast revenue HKD 146.93 B, EPS HKD 0.448

CR Medicine Co., Ltd Subsidiaries Participate in Establishing Biomedical Investment Fund

HKC INT'L RTS

TIANBAO ENERGY

HANG YICK RTS

KWAN ON RTS

SINO GAS HLDGS

NEWTON RES

AGTECH HOLDINGS

CHERISH SUN

K W NELSON GP

HK ENT INTL

588130

159892

159316

520880

159615

510660

159837

159992

588860

520690

588250

159859

512290

516930

516820

159506

03320

513700

159929

159849

China Resources Pharma announced that its subsidiary China Resources BOYA Biotechnology Group has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for human coagulation factor IX. This product is used for bleeding treatment in patients with coagulation factor IX deficiency (Hemophilia B)

AASTOCKS

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

BOYA BIOLOGY

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai SSE STAR Brand Name Drug ETF

E Fund CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

ICBCCS SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

Guotai CSI Bio-medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

CHINARES PHARMA

Penghua CSI HK Connect Health Care Composite ETF

China Universal 800 Health Care ETF

Huaan Hang Seng Biotech ETF

Bosera Hang Seng Health Care ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

China Resources Pharma's recombinant coagulation factor IX has received the clinical trial approval notice for drugs in mainland China

000423

China Resources Pharmaceutical Group Ltd. announced an investment of approximately RMB 1.421 billion by its subsidiary, Dong-E-E-Jiao Company Limited, to construct a Health Consumer Products Industrial Park. The project will encompass manufacturing, warehousing, and logistics facilities, funded by internal resources. This investment aims to enhance the company's health consumer products business and support its strategic growth model.

Reuters

DEEJ

China Resources Pharmaceutical Invests in Health Consumer Products Industrial Park

China Resources Pharmaceutical Group Ltd. is looking to sell a 17.87% stake in Hefei Tianmai Biotechnology Development Co., Ltd. through a public tender on the Shanghai United Assets and Equity Exchange. The minimum listing price is approximately RMB 1.42 billion. As of now, no buyer has been identified, and the process will end if a suitable transferee is not found.

CS精准医

China Resources Pharmaceutical Group Seeks to Sell 17.87% Stake in Tianmai Biotechnology

000999

China Resources Pharmaceutical announced that its subsidiary China Resources Sanjiu's preliminary performance for the year 2025 shows total operating revenue of RMB 31.629 billion, an increase of 14.5% year-on-year. Net profit attributable to shareholders is RMB 3.422 billion, an increase of 1.6%

CR Sanjiu

CR Sanjiu, a subsidiary of CHINARES PHARMA, reported a net profit of 3.422 billion RMB for the year, an increase of 1.6%

China Resources Pharmaceutical announced that its subsidiary KPC's preliminary performance for the year 2025 is expected to show a total operating revenue of 6.577 billion RMB, a year-on-year decrease of 21.7%, due to a decline in both the sales scale and gross profit margin of the group's products. The net profit attributable to shareholders is expected to be 350 million RMB, a decline of 46%

China Resources Pharmaceutical's subsidiary KPC earned 350 million RMB last year, a decline of 46%

China Resources Pharmaceutical Group Ltd. held an extraordinary general meeting on February 6, 2026. The proposed items, including the approval of ongoing connected transactions under the Sales Framework Agreement 2026/2028 and amendments to the articles of association, were each approved.

China Resources Pharmaceutical Group Ltd. hielt außerordentliche Hauptversammlung ab

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu), a subsidiary of China Resources Pharmaceutical Group Ltd., reported a 14.53% increase in total operating revenue, reaching RMB31.629 billion for the year ending December 31, 2025. The net profit attributable to shareholders rose by 1.60% to RMB3.422 billion. This information was published by China Resources Pharmaceutical Group Ltd. via the Hong Kong Stock Exchange.

CR Sanjiu Posts 14.53% Revenue Growth Under China Resources Pharmaceutical Group

Tasly Pharmaceutical Group Co., Ltd., an associate of China Resources Pharmaceutical Group, reported preliminary unaudited financial results for 2025. The company, holding approximately 28% of shares through its subsidiary, noted successful integration with CR Sanjiu and accelerated resource bundling. However, revenues in pharmaceutical trading, particularly in the pharmacy sector, declined by 14.24% year-over-year due to industry-wide policy measures.

TASLY

Tasly Pharmaceutical meldet vorläufige Jahreszahlen 2025 als assoziiertes Unternehmen von China Resources Pharmaceutical Group

JPCRPHA@EC2611A(24589.HK)

China Resources Pharma's recombinant coagulation factor IX has received the clinical trial approval notice for drugs in mainland China

China Resources Pharmaceutical Invests in Health Consumer Products Industrial Park

China Resources Pharmaceutical Group Seeks to Sell 17.87% Stake in Tianmai Biotechnology

CR Sanjiu, a subsidiary of CHINARES PHARMA, reported a net profit of 3.422 billion RMB for the year, an increase of 1.6%

China Resources Pharmaceutical's subsidiary KPC earned 350 million RMB last year, a decline of 46%